Primary and Secondary (Non-Genetic) Causes of Focal and Segmental Glomerulosclerosis

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 228-240

  Appel, Gerald B ^a   D'Agati, Vivette D ^a  

^a New York Presbyterian Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959338889     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00018-6     Document Type: Chapter

References (71)

1. Aggarwal N, Appel GB Focal segmental glomerulosclerosis. Primer on Kidney Diseases 2009, 165-170. WB Saunders, Philadelphia. 5th ed. A. Greenberg (Ed.).
2. Meyrier A Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005, 1:44-54.
3. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ FSGS in nephrotic adults: Presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004, 15:2169-2177.
4. D'Agati V Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003, 23:117-135.
5. D'Agati VD Focal segmental glomerulosclerosis. Atlas of Nontumor Pathology: Nonneoplastic Kidney Diseases 2005, 125-159. American Registry of Pathology Press, Silver Spring, Md. V. D'Agati, J.C. Jennette, F.S. Silva (Eds.).
6. Kitiyakara C, Eggers P, Kopp JB Twenty-one year trends in ESRD due to FSGS in the United States. Am J Kidney Dis 2004, 44:815-825.
7. D'Agati VD The spectrum of focal segmental glomerulosclerosis: New insights. Curr Opin Nephrol Hypertens 2008, 17:271-281.
8. D'Agati VD Podocyte injury in focal segmental glomerulosclerosis. Lessons from animal models. Kidney Int 2008, 73:399-406.
9. Ichikawa I, Ma J, Motojima M, Matsusaka T Podocyte damage damages podocytes: Autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 2005, 14:205-210.
10. Ijpelaar DH, Farris AB, Goemaere N, et al. Fidelity and evolution of recurrent focal segmental glomerulosclerosis in renal allografts. J Am Soc Nephrol 2008, 19:2219-2224.
11. Savin VJ, McCarthy ET, Sharma M Permeability factors in FSGS. Semin Nephrol 2003, 23:147-161.
12. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein absorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994, 330:7-11.
13. Matalon A, Markowitz GS, Joseph RE, et al. Plasmapheresis treatment of recurrent FSGS in adult transplant recipients. Clin Nephrol 2001, 56:271-278.
14. Savin VJ, Sharma M, McCarthy ET, et al. Cardiotrophin like cytokine-1: Candidate for the focal glomerular sclerosis permeability factor. J Am Soc Nephrol 2008, 19:59A.
15. Sellier-Leclerc AL, Duval A, Riveron S, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007, 18:2732-2739.
16. Le Berre L, Bruneau S, Naulet J, et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol 2009, 20:57-67.
17. Del Carmen Avila-Casado M, Perez-Torres I, Auron A, et al. Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. Kidney Int 2004, 66:133-143.
18. Kambham N, Markowitz GS, Valeri AM, et al. Obesity related glomerulomegaly: An emerging epidemic. Kidney Int 2001, 59:1498-1509.
19. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
20. Genovese G, Friedman DJ, Ross MD, et al. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. Science 2010, in press.
21. Moudgil A, Nast CC, Bagga A, et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001, 59:2126-2133.
22. Markowitz GS, Nasr SH, Stokes MB, D'Agati VD Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5:607-615.
23. Kunis CL, Aggarwal N, Appel GB Illicit drug abuse and renal disease. Clinical Nephrotoxins 2008, 595-617. Springer, New York. 3rd ed. M.E. De Broe, G.A. Porter (Eds.).
24. Markowitz G, Appel GB, Fine P, et al. Collapsing focal segmental glomerulosclerosis following treatment with high dose pamidronate. J Am Soc Nephrol 2001, 12:1164-1172.
25. Herlitz LC, Markowitz GS, Farris AB, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010, 21:163-172.
26. Schwimmer JA, Markowitz GS, Valeri A, et al. Secondary FSGS in non-obese patients with increased muscle mass. Clin Nephrol 2003, 60:233-241.
27. Hodgin JB, Rasoulpour M, Markowitz GS, D'Agati VD Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4:71-76.
28. Barisoni L, Kriz W, Mundel P, D'Agati V The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic FSGS and HIV associated nephropathy. J Am Soc Nephrol 1999, 10:51-61.
29. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: Role in podocyte proliferation and maturation. Kidney Int 2000, 58:674-683.
30. Kim JH, Kim BK, Moon KC, et al. Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003, 64:1715-1721.
31. Haas M, Meehan S, Karrison TG, Spargo BH Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997, 30:621-631.
32. Bahiense-Oliveira M, Saldanha LB, Andrade Mota EL, et al. Primary glomerular disease in Brazil: 1979-1999. Is the frequency of FSGS increasing?. Clin Nephrol 2004, 61:90-97.
33. Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study. Clin J Am Soc Nephrol 2006, 1:483-487.
34. Hanko JB, Mullan RN, O'Rourke DM, McNamee PT, Maxwell AP, Courtney AE The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009, 24:3050-3054.
35. Stokes MB, Markowitz GSM, Lin J, et al. Glomerular tip lesion: A distinct entity within the minimal change/focal segmental glomerulosclerosis spectrum. Kidney Int 2004, 65:1690-1702.
36. Valeri A, Barisoni L, Appel GB, et al. Idiopathic collapsing FSGS: A clinicopathologic study. Kidney Int 1996, 50:1734-1746.
37. Schwimmer JA, Markowitz GS, Valeri A, Appel GB Collapsing glomerulopathy. Semin Nephrol 2003, 23:209-219.
38. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004, 43:368-382.
39. Markowitz GS, Schwimmer JA, Stokes MB, et al. C1q nephropathy: A variant of focal segmental glomerulosclerosis. Kidney Int 2003, 64:1232-1240.
40. Vizjak A, Ferluga D, Rozic M, et al. Pathology, clinical presentations and outcomes of C1q nephropathy. J Am Soc Nephrol 2008, 19:2237-2244.
41. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int 2006, 70:1783-1792.
42. Wyatt CM, Klotman PE, D'Agati VD HIV-associated nephropathy: Clinical presentation, pathology and epidemiology in the era of antiretroviral therapy. Semin Nephrol 2008, 28:513-522.
43. Deegens JKJ, Dijkman HB, Borm GF, et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008, 74:1568-1576.
44. Stirling CM, Mathieson P, Bolton-Jones JM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. Q J Med 2005, 98:443-449.
45. Pei Y, Cattran D, Delmore T, et al. Evidence suggesting under-treatment of adults with idiopathic FSGS. Am J Med 1987, 82:938-944.
46. Matalon A, Valeri A, Appel GB Treatment of focal segmental glomerulosclerosis. Semin Nephrol 2000, 20:309-317.
47. Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 2005, 16:1061-1068.
48. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006, 69:920-926.
49. Howie AJ, Pankhurst T, Sarioglu S, et al. Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int 2005, 67:987-1001.
50. Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis of FSGS?. Am J Kidney Dis 1999, 34:618-625.
51. Korbet SM Treatment of primary focal and segmental glomerulosclerosis. Kidney Int 2002, 62:2301-2310.
52. Ponticelli C, Passerini P Other immunosuppressive agents for FSGS. Semin Nephrol 2003, 23:242-248.
53. Tune BM, Kirpekor R, Sibley R, et al. IV methylprednisolone and oral alkylating agent therapy of prednisone resistant pediatric FSGS: Long-term follow up. Clin Nephrol 1995, 43:83-88.
54. Lieberman KV, Tejani A A randomized double-blind trial of cyclosporine in steroid resistant FSGS in children. J Am Soc Nephrol 1996, 7:56-63. for the NY-NJ Pediatric Nephrology Study Group.
55. Cattran D, Appel GB, Hebert L, et al. A randomized trial of cyclosporine in patients with steroid resistant focal segmental glomerulosclerosis: North America Nephrotic Syndrome Study Group. Kidney Int 1999, 56:2220-2226.
56. Duncan N, Dhaygude A, Owen J, et al. Treatment of focal segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004, 19:3062-3063.
57. Loeffler K, Gowrishankar M, Yiu V Tacrolimus therapy in pediatric patients with treatment resistant nephrotic syndrome. Pediartr Nephrol 2004, 19:281-287.
58. Heering P, Braun N, Mullejans R, et al. Cyclosporin A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004, 43:10-18.
59. Cattran DC, Wang MM, Appel GB, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2005, 62:405-412.
60. Appel AS, Appel GB An update on the use of mycophenolate in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 2009, 5:132-142.
61. Fervenza F, Fitzpatrick PM, Mertz J, et al. Acute rapamycin nephrotoxicity in native kidneys in patients with chronic glomerulopathies. Nephrol Dial Transplant 2004, 19:1288-1292.
62. Tumlin JA, Miller D, Near M, et al. A prospective open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006, 1:109-117.
63. Fernandez-Fresnedo G, Segarra A, Gonzalez E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4:1317-1323.
64. Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003, 42:1121-1130.
65. Savin VJ, McCarthy ET, Sharma R, et al. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 2008, 151:288-292.
66. De Smet E, Rioux JP, Ammann H, et al. FSGS permeability factor-associated nephrotic syndrome: Remission after oral galactose therapy. Nephrol Dial Transplant 2009, 24:2938-2940.
67. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2:906-913.
68. Vincenti F, Ghiggeri GM New insights into the pathogenesis and the therapy of recurrent FSGS. Am J Transplant 2005, 5:1179-1185.
69. Huang K, Ferris ME, Andreoni KA, Gipson DS The differential effect of race among pediatric kidney transplant recipients with FSGS. Am J Kidney Dis 2004, 43:1082-1090.
70. Cibrik DM, Kaplan B, Campbell DA, Meier-Kriesche HU Renal allograft survival in transplant recipients with focal glomerulosclerosis. Am J Transplant 2003, 3:64-67.
71. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 1995, 25:534-542.